Clinical Trial Search

Primary: Number of Participants Showing Improvement or no Further Progression of Motor Deficits at 1 Month Following Radiotherapy — 68; 69 Participants

Primary: Number of Participants Who Were Alive at 6 Months After Radiotherapy Without Deterioration of Motor Function During (or Directly After) Radiotherapy and Freedom From…

Primary: Pain Response as Measured by VAS at 3 Months — 8; 12; 1 Participants

Primary: Number of Participants With Radiographic Recurrence at 12 Months — 3 Participants

Primary: Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation (Phase II) — 39; 37 Participants

Primary: Number of Participants to Receive Delivery of the First Fraction of Same-session MRI-only Simulation and Treatment With SMART on the First On-table Attempt — 8…

Primary: Initial Symptom Control — 3; 28; 3; 27 Participants

Primary: Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single Session — 18 Participants

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Distance Between the Gross Disease and Spinal Cord (Cord-disease Distance, CDD) of at Least 3mm After Treatment. — 1; 14 Participants

Primary: Phase III: Complete Pain Response at 3 Months Post-radiation — 16; 40; 29; 20 Participants — p=0.0002

Primary: Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires — 3.4; 65.2 points on a…

Primary: Kinematics — 15.5; 10 degrees

Primary: Local Tumor Control Using MRI or CT

Primary: The Average Time From HBO Chamber Exit to SRS beam-on — 8.3 minutes

Primary: Toxicity — 14; 0; 0; 0 participants

Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042

Primary: Time to Progression — 317 Days

Primary: Number of Participants Who Achieved a Clinically Significant Improvement in the Oswestry Disability Index at 12 Months — 83; 35 Participants

Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Freedom From Serious Adverse Events Rate — 18 Participants

Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001

Primary: Local Control — 13; 23; 2; 1 participants

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: Time to Treatment Failure (TTF) Compared Between Treatment Groups. — 5.7; 8.3 months

Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients

Primary: Proportion of Evaluable Participants Who Experience a Partial Response (PR) or Complete Response (CR) Reported Along With an 80% Confidence Interval. — 0.1; 0; 0.2; 0…

Primary: Time to Neurocognitive Failure — 68.2; 59.3 percentage of participants — p=0.029

Primary: Number of Responders — 54; 6 Participants